Alfred Altomari - Jun 28, 2023 Form 4 Insider Report for AGILE THERAPEUTICS INC (AGRX)

Role: Chief Executive Officer, Director
Signature: /s/ Geoffrey P. Gilmore. Attorney-in-fact
Stock symbol: AGRX
Transactions as of: Jun 28, 2023
Transactions value $: $0
Form type: 4
Date filed: 6/30/2023, 04:37 PM
Previous filing: May 15, 2023
Next filing: May 15, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AGRX	Common Stock	Award	$0	+37.5K	+2916.02%	$0.00	38.8K	Jun 28, 2023	Direct	F1, F2
transaction	AGRX	Common Stock	Award	$0	+8.96K	+23.11%	$0.00	47.7K	Jun 28, 2023	Direct	F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AGRX	Employee Stock Option (Right to Buy)	Award	$0	+12.5K		$0.00	12.5K	Jun 28, 2023	Common Stock	12.5K	$2.48	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares represent restricted stock units ("RSUs") which were granted on June 28, 2023. The RSUs will vest in four equal installments over four years upon the anniversary of the grant, such that the RSUs will be fully vested on June 28, 2027.
F2	On April 10, 2023, the Issuer completed a one-for-fifty reverse stock split of the Issuer's common stock. This amount has been adjusted to give effect to this reverse stock split.
F3	These shares represent RSUs that were granted on June 28, 2023, which will vest and be settled in common stock on June 28, 2024.
F4	This option was granted on June 28, 2023. 25% of the shares subject to the stock option vest on June 28, 2024, and the remaining shares vest in 36 substantially equal monthly installments over the following three years such that the option will be fully vested on June 28, 2027.